From Data to Decisions: Getting More from Clinical Trial Evidence
Matt Zierhut, PhD MBAOctober 13, 2026
Strategy Starts at Discovery: Using QSP to Choose the Right Indication, the Right Asset, and the Right Path to First-in-Human
Watch the webinar to learn how QSP and a model-informed target product profile guide indication,…
Danielle PillsburyOctober 9, 2026
Drug-Drug Interaction (DDI) Calculator
The DDI Calculator within the Drug Interaction Database (DIDB) is a tool designed to quantitatively…
CertaraOctober 8, 2026
Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV
Explore population PK modeling of dolutegravir in plasma and cerebrospinal fluid to characterize CNS penetration…
CertaraOctober 5, 2026
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma
Explore a simultaneous population PK/PD model characterizing the dynamic relationships between belantamab mafodotin, sBCMA, and…
CertaraOctober 5, 2026
Get the Presentation: Building Investor-Ready Biotech Strategies
Get the full presentation from Certara's Biotech Forum on building investor-ready development strategies ahead of…
Diana Marcantonio, PhDSeptember 29, 2026
Model-Informed Strategies for ADC Development
Explore how model informed drug development can help ADC developers optimize dosing, reduce uncertainty, strengthen…
Danielle PillsburySeptember 22, 2026
When EV Dose Is Not What It Seems: Quantitative Mismatch Between Particle Number- and Protein-Based Dosing
Research shows that particle- and protein-based extracellular vesicle dosing are not interchangeable, supporting a multidimensional…
CertaraSeptember 18, 2026
